Go Ad-Free
logoThe People's Perspective on Medicine

Nicotine Patch for Alzheimer’s—Could Nicotine Help You Remember?

Nicotine patch to the rescue? The dementia drug no one saw coming even though researchers have been considering this compound for decades.

For decades researchers have considered nicotine a serious health problem. It is, after all, the addicting compound in cigarettes and other tobacco products. Humans have apparently been using tobacco as a drug for over 12,000 years (Nature Human Behavior, Feb. 2022). It has been smoked, snuffed and chewed. More recently, drug companies have created the nicotine patch. It is supposed to help people stop smoking. Could it also help people who are suffering from Alzheimer disease?

A Short History of Nicotine and Dementia:

By the 1970s researchers were beginning to identify acetylcholine as a key problem in Alzheimer’s disease (Brain Research, Dec. 16, 1977). This critical neurotransmitter was deficient in the brains of patients with AD (Alzheimer’s disease).

Researchers writing in the Annals of Neurology (June, 1978) noted:

“Damage to the hippocampal formation, whether focal or diffuse, leads to severe impairment of short-term memory. The most common presenting symptom of Alzheimer disease is loss of short-term memory, and histologically the hippocampus is characteristically affected. Choline acetyltransferase, which is involved in the synthesis of acetylcholine, is depleted in the hippocampus in the disorder. Anticholinergic drugs administered to normal subjects can simulate some aspects of the memory defect seen in Alzheimer disease. It is postulated that damage to a cholinergic neuronal pathway running to or from the hippocampus underlies the memory disorder. This suggestion implies that it may be possible to improve memory in patients with Alzheimer disease by pharmacological means.”

Did your eyes glaze over or did you grasp the meaning of that last sentence? These scientists were suggesting that you might be able to “improve memory” with drugs that somehow enhance cholinergic neurons.

They go on to state that:

“Moreover, there is pharmacologic evidence that the neurotransmitter acetylcholine is involved in memory processes in man.”

Guess what? Nicotine stimulates acetylcholine receptors in the brain.

What About a Nicotine Patch to Stimulate Cholinergic Receptors?

The Alzheimer’s Society has even gone so far as to ask this question:

“Can nicotine reduce dementia risk”

“There is some evidence that exposure to nicotine, which is one of the components of cigarette smoke, can actually reduce the risk of dementia. Such reports may be useful in indicating possible research directions for drug design.

“However, nicotine intake through smoking would not be beneficial. Any positive effects would be outweighed by the significant harm caused by the other toxic components in cigarette smoke.”

This brings us to a recent question from a visitor to this website.

A Reader Asks About Using the Nicotine Patch for Dementia?

Q. My brother is approaching 81 and is having difficulties with his memory. His doctor has prescribed donepezil.

As far as I can tell, investigation on drugs that help with dementia and Alzheimer’s is inconclusive. I have been reading more and more about the nicotine patch.

I have great respect for your opinion. What are your thoughts about the nicotine patch? Are there any clinical trials that might establish effectiveness?

We have a family history. Our mother and many of her siblings died from Alzheimer’s.

A. You have asked a fascinating question. We have known for years that nicotine patches might have a beneficial effect on memory (Psychopharmacology, Feb. 2004).

Here is the scientists’ introduction:

“Chronic transdermal nicotine has been found to improve attentional performance in patients with Alzheimer’s disease (AD), but little is known about chronic nicotine effects in age-associated memory impairment (AAMI), a milder form of cognitive dysfunction. The current study was performed to determine the clinical and neuropsychological effects of chronic transdermal nicotine in AAMI subjects over a 4-week period.”

This was a small study of people with age-associated memory impairment.

Conclusions Regarding the Nicotine Patch:

“Chronic transdermal nicotine treatment in AAMI subjects caused a sustained improvement in clinical symptoms and objective computerized tests of attention. These results support the further investigation of nicotinic treatment as a promising therapy for AAMI.”

More Nicotine Patch Research:

In 2013 Finnish researchers pointed out that (Duodecim, 2013):

“even a noxious substance may possess beneficial properties”

They too reported that a nicotine patch could improve symptoms of mild cognitive impairment.

Other pilot studies have reinforced some benefit from nicotine patch treatment (Neurology, Jan. 10, 2012):

“This study found that transdermal nicotine over 6 months is a safe treatment for nonsmoking subjects with MCI [mild cognitive impairment]. As this was a pilot clinical trial, we wanted to measure a broad number of cognitive and behavioral domains which might be influenced by nicotinic stimulation. Thus, it is not surprising that some measures showed no effect of treatment. However, measures of attentional, memory, and psychomotor performance did show an effect of nicotine and this finding provides strong justification for further treatment studies of nicotine for patients with early evidence of cognitive dysfunction.”

The MIND Clinical Trial:

We have been waiting a long time for a large nicotine patch study to be conducted. Let’s face it, the patch is a relatively inexpensive pharmaceutical product that can be purchased over the counter to help people quit smoking. Drug companies like big ticket products.

The first big study of nicotine patches for patients with mild cognitive impairment is called MIND (Memory Improvement Through Nicotine Dosing). This clinical trial should be completed this year. We look forward to learning the results. When they are announced, we will do our best to make them available to you in a timely manner. Until then, though, we cannot recommend this approach. Anyone contemplating such an approach must discuss it with a physician. Nicotine could interact with other prescribed medications for AD.

Have you ever used the nicotine patch to quit smoking? Please share your experience in the comment section below. If you think this article is intriguing, please share it with friends and family. We would be grateful if you encourage them to sign up for our free newsletter at this link. Thank you for supporting our work.

Citations
  • Newhouse, P., et al, "Nicotine treatment of mild cognitive impairment," Neurology, Jan. 10, 2012, doi: 10.1212/WNL.0b013e31823efcbb
  • White, H.K. and Levin, E.D., "Chronic transdermal nicotine patch treatment effects on cognitive performance in age-associated memory impairment," Psychopharmacology, Feb. 2004, doi: 10.1007/s00213-003-1614-8
Rate this article
star-fullstar-emptystar-fullstar-emptystar-fullstar-emptystar-fullstar-emptystar-fullstar-emptystar-fullstar-emptystar-fullstar-emptystar-fullstar-emptystar-fullstar-emptystar-fullstar-empty
4.6- 52 ratings
About the Author
Joe Graedon is a pharmacologist who has dedicated his career to making drug information understandable to consumers. His best-selling book, The People’s Pharmacy, was published in 1976 and led to a syndicated newspaper column, syndicated public radio show and web site. In 2006, Long Island University awarded him an honorary doctorate as “one of the country's leading drug experts for the consumer.”.
Tired of the ads on our website?

Now you can browse our website completely ad-free for just $5 / month. Stay up to date on breaking health news and support our work without the distraction of advertisements.

Browse our website ad-free
Join over 150,000 Subscribers at The People's Pharmacy

We're empowering you to make wise decisions about your own health, by providing you with essential health information about both medical and alternative treatment options.